BigHat Bio
Amol is a healthcare finance executive and Head of Corporate Development at Zentalis Pharmaceuticals. Prior to Zentalis Amol was an investment banker at PJT Partners and Deutsche Bank with additional time in equity research covering SMID-cap biotech companies at Stifel. Amol has also spent time at healthcare startup companies in the fields of neurology and high throughput histopathology. He received a PhD in Chemistry from the University of Cambridge as a Gates Scholar as well as an MS (Chemistry) and BA (Biochemistry) at the University of Pennsylvania as a Vagelos Scholar.
This person is not in the org chart
This person is not in any offices
BigHat Bio
1 followers
BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.